NCT06402630View on ClinicalTrials.gov

A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)

PHASE2CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

March 23, 2022

Primary Completion Date

April 1, 2024

Study Completion Date

April 1, 2024

Conditions
Alopecia Areata
Interventions
DRUG

STS01

Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.

DRUG

Placebo

Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.

Trial Locations (9)

KY12 0SU

Queen Margaret Hospital, Glasgow

BD5 0NA

St Lukes Hospital, Bradford

BN2 5BE

Royal Alexandra Children's Hospital, Brighton

CV2 2DX

University Hospital Coventry & Warwickshire, Coventry

G51 4TF

Queen Elizabeth University Hospital, Glasgow

GL1 3NN

Gloucestershire Royal Hospital, Gloucester

W1G 8HU

Queen Anne Street Medical Centre Limited, London

NR4 7UY

Norfolk and Norwich University Hospital, Norwich

M6 8HD

Salford Royal Hospital, Salford

All Listed Sponsors
lead

Soterios Ltd

INDUSTRY